Table 2 Details of SRA seroconversion in... | American Society of Hematology

Table 2

Details of SRA seroconversion in 13 heparin reexposures performed for cardiac or vascular surgery

Patient	Serotonin-release (%) at concentrations of UFH				Platelet count decrease >30% or thrombosis on or after POD5
Patient	0	0.1	0.3	100	Platelet count decrease >30% or thrombosis on or after POD5
3	37	59	83	50	No
8	1	17	84	1	No
10	0	11	73	0	No
11	0	75	89	0	No
14	0	50	100	17	No
15	54	89	96	24	No
16	1	47	88	1	No
17	95	100	98	2	HIT: 86% platelet decrease from 148 to 20 beginning on POD7 (Figure 4)
22	4 (79*)	82	89	1	No; however, atrial fibrillation developed on POD14, and in vitro cross-reactivity (79% serotonin release) with danaparoid 0.3 anti-Xa U/mL was shown (Figure 4)

Patient	Serotonin-release (%) at concentrations of UFH				Platelet count decrease >30% or thrombosis on or after POD5
Patient	0	0.1	0.3	100	Platelet count decrease >30% or thrombosis on or after POD5
3	37	59	83	50	No
8	1	17	84	1	No
10	0	11	73	0	No
11	0	75	89	0	No
14	0	50	100	17	No
15	54	89	96	24	No
16	1	47	88	1	No
17	95	100	98	2	HIT: 86% platelet decrease from 148 to 20 beginning on POD7 (Figure 4)
22	4 (79*)	82	89	1	No; however, atrial fibrillation developed on POD14, and in vitro cross-reactivity (79% serotonin release) with danaparoid 0.3 anti-Xa U/mL was shown (Figure 4)

In vitro cross-reactivity (79% serotonin release) with danaparoid 0.3 anti-Xa U/mL was demonstrated (Figure 2).